Full Text View
Tabular View
No Study Results Posted
Related Studies
Telemedicine Influence in the Follow up of the Type 2 Diabetes Patient
This study has been completed.
First Received: September 7, 2007   No Changes Posted
Sponsors and Collaborators: Province of Malaga Health Department
Hoffmann-La Roche
Information provided by: Province of Malaga Health Department
ClinicalTrials.gov Identifier: NCT00527254
  Purpose

The purpose of this study is to evaluate the impact of a a real time teleassistance system in the clinical evolution of type 2 diabetic patients on self monitoring blood glucose in the Public National Primary Care System.


Condition Intervention
Type 2 Diabetes
Telemedicine
Self Monitoring Blood Glucose
Primary Care
Device: Telemedicine system

MedlinePlus related topics: Diabetes
U.S. FDA Resources
Study Type: Interventional
Study Design: Supportive Care, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Further study details as provided by Province of Malaga Health Department:

Primary Outcome Measures:
  • HBA1c Glycosylated hemoglobin [ Time Frame: one year for every patient ]

Secondary Outcome Measures:
  • Blood glucose, Total Cholesterol, HDL Cholesterol,LDL Cholesterol, Triglycerides, BMI, systolic and diastolic blood pressure and system adherence [ Time Frame: one year for every patient ]

Enrollment: 328
Study Start Date: October 2003
Study Completion Date: June 2005
Arms Assigned Interventions
Control group: No Intervention
Telemedicine group: Active Comparator Device: Telemedicine system
Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.

Detailed Description:

The UKPDS study in type 2 diabetes and the DCCT in type 1, showed that intensive blood glucose control and the following HBA1c decrease were associated with a decrease of diabetic complications. Introducing telecontrol elements in the real time follow up of the patients, should help to know continuously patient blood glucose profile and add if necessary immediately therapeutical variations, to maintain HbA1c levels as low as possible. The study compares type 2 diabetes patients performing self monitoring of blood glucose, followed up by their family doctor in their primary care unit with the extra support of a real time teleassistance system with type 2 diabetes patients performing self monitoring of blood glucose, followed up by their family doctor in their primary care unit.

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of type 2 Diabetes
  • on SMBG al least 6 months before
  • age superior of 30 years
  • controlled in province of Málaga Primary Care Units

Exclusion Criteria:

  • having diabetic complications or other diseases that could make difficult to use the telemedicine system
  • patients who need a carer
  • not passing the initial training (low cultural level)
  • living in an area without mobile phone coverage
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00527254

Locations
Spain
Province of Malaga Health Department
Málaga, Spain, 29001
Sponsors and Collaborators
Province of Malaga Health Department
Hoffmann-La Roche
Investigators
Principal Investigator: Maria Isabel Rodríguez Idígoras, Doctor Málaga Health Department (Junta de Andalucia)
  More Information

No publications provided

Study ID Numbers: TeleDiabecom 200501
Study First Received: September 7, 2007
Last Updated: September 7, 2007
ClinicalTrials.gov Identifier: NCT00527254     History of Changes
Health Authority: Spain: Comité Ético de Investigación Clínica

Study placed in the following topic categories:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder

Additional relevant MeSH terms:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on May 07, 2009